TY - JOUR
T1 - Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type
AU - Tariot, Pierre N.
AU - Goldstein, Bonnie
AU - Podgorski, Carol Ann
AU - Cox, Christopher
AU - Frambes, Nancy
N1 - Funding Information:
This work was supported by grants from the National Institute of Mental Health (MH 00733, MH 403818) and the National Institute on Aging (AG 08665) .
PY - 1998
Y1 - 1998
N2 - As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-tPlanmoderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug- placebo difference in any outcome measure. Selegiline did not show short- term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.
AB - As a follow-up to an earlier study showing short-term benefit in inpatients with more severe dementia, the authors studied the short-term cognitive, functional, and behavioral effects of selegiline in outpatients with mild-tPlanmoderate dementia of the Alzheimer type (DAT) by means of a double-blind, randomized, crossover study of placebo vs. selegiline. Fifty outpatients with mild-to-moderate DAT and no behavioral disturbances were given selegiline in two 8-week treatment periods separated by a 4-week washout. Outcome was assessed with standardized measures of dementia severity, daily functioning, behavior, and cognition. There was no drug- placebo difference in any outcome measure. Selegiline did not show short- term benefit in this study, contrary to the earlier study, perhaps because the patients were studied less intensively and/or lacked behavioral problems that could show response, although the medication was well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0031946037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031946037&partnerID=8YFLogxK
U2 - 10.1097/00019442-199805000-00008
DO - 10.1097/00019442-199805000-00008
M3 - Article
C2 - 9581210
AN - SCOPUS:0031946037
SN - 1064-7481
VL - 6
SP - 145
EP - 154
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 2
ER -